The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monoclonal antibodies, and precision medicine. North America leads the market, with Europe and Asia-Pacific also showing strong growth due to improved healthcare infrastructure and increasing adoption of biologics and biosimilars. Pharmaceutical companies are investing in next-generation immunotherapies and personalized treatments to improve patient outcomes and slow disease progression.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Trupanion, a pet insurance provider, operates in the growing pet care market with subscription plans for cats and dogs. Despite a recent 2.68% dip, the stock has gained 4.13% over 30 days, indicating positive momentum and a potential buying opportuni...
Cass Information Systems reported strong first-quarter earnings of $0.66 per share, beating estimates, and achieved record annual net income of $35.1 million. The company is improving operational efficiency through automation and workforce reductions...
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
Citigroup lowered its price target for Ericsson to SEK 105 from SEK 110 and kept a Neutral rating after the company's Q2 2026 results missed revenue and earnings estimates. Ericsson's shares dropped over 13% due to rising component costs, especially ...
